RECRUITINGINTERVENTIONAL

XOR Levels in OSA Patients (XOR-OSA)

Obstructive Sleep Apnea Severity and Xanthine Oxidoreductase Activity: Mechanisms and Clinical Implications

About This Trial

The level of xanthine oxidoreductase (XOR) in plasma is associated with oxidative stress and inflammation. Obstructive Sleep Apnea (OSA) is characterized by repeated upper airway obstruction and apneas during sleep, leading to chronic intermittent hypoxemia. The specific role of XOR in OSA, its relationship with the severity of OSA, and the changes in XOR levels before and after CPAP treatment remain unclear. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University, categorized by their Apnea-Hypopnea Index (AHI) into mild, moderate, and severe OSA groups. Participants will undergo baseline assessments including polysomnography (PSG) and measurements of XOR activity and biomarkers such as uric acid, endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), and inflammatory markers. Eligible patients will receive CPAP treatment for 3 months, after which their XOR activity and biomarker levels will be re-evaluated to assess treatment efficacy.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients aged between 18 and 80 years. 2. Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h). 3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA. 4. Ability and willingness to provide willing to sign a consent form for participation in the study. Who Should NOT Join This Trial: 1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results. 2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases. 3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition. 4. Pregnancy or having other conditions that make participation in this study unsuitable. 5. Extremely debilitated patients or those with severe underlying conditions. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Patients aged between 18 and 80 years. 2. Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h). 3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA. 4. Ability and willingness to provide informed consent for participation in the study. Exclusion Criteria: 1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results. 2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases. 3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition. 4. Pregnancy or having other conditions that make participation in this study unsuitable. 5. Extremely debilitated patients or those with severe underlying conditions.

Treatments Being Tested

DEVICE

CPAP Treatment

Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.

Locations (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China